Notably, ERBB2 mutations in NSCLC are typically mutually exclusive of other driver mutations, such as EGFR, KRAS, and ALK rearrangements, highlighting their potential to serve as distinct therapeutic targets [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.